United States Biosimilars Market to hit US$ 171.79 Billion by 2033 | Top Companies 2025 - Amgen Inc., Pfizer Inc., Sandoz Group AG

"Global biosimilars market size reached US$ 22.58 billion in 2024 and is expected to reach US$ 171.79 billion by 2033, growing at a CAGR of 25.5% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/biosimilars-market?sp

United States: Recent Industry Developments

✅ In September 2025, Amgen launched a biosimilar to Stelara for autoimmune diseases in the U.S. market. The therapy offers a lower-cost alternative for patients with psoriasis and Crohn's disease. Early uptake highlights strong demand for affordable biologics.

✅ In August 2025, Pfizer invested $120 million in expanding its biosimilars manufacturing facility in North Carolina. The expansion supports large-scale production of oncology and immunology biosimilars. It is expected to strengthen supply reliability in the U.S.

✅ In July 2025, Biocon Biologics introduced an adalimumab biosimilar in partnership with U.S. distributors. The product is priced competitively to increase patient access. Market entry signals intensifying competition in the anti-inflammatory segment.

✅ In June 2025, Coherus BioSciences launched a ranibizumab biosimilar for ophthalmology treatments. The therapy addresses retinal disorders with significant cost savings. Early adoption by clinics demonstrates strong acceptance in the eye-care market.

Japan: Recent Industry Developments

✅ In September 2025, Fujifilm Kyowa Kirin Biologics launched a bevacizumab biosimilar for oncology in Japan. The product targets colorectal and lung cancer treatments. Initial rollouts show rapid uptake among hospitals seeking cost-effective therapies.

✅ In August 2025, Nippon Kayaku invested ¥18 billion to scale biosimilars production capacity. The facility will focus on monoclonal antibody biosimilars. The investment aims to meet growing domestic and Asia-Pacific market demand.

✅ In July 2025, Daiichi Sankyo introduced a rituximab biosimilar for hematologic malignancies. The biosimilar provides a lower-cost option for patients requiring long-term therapy. Clinical feedback highlights strong efficacy and safety outcomes.

✅ In June 2025, Meiji Seika Pharma partnered with local healthcare providers to expand biosimilars adoption. The collaboration includes awareness programs for physicians and patients. Early results indicate broader acceptance and increased prescription rates.

Biosimilars Market: Drivers

The biosimilars market is experiencing rapid growth due to increasing demand for affordable and accessible biologic therapies across chronic and complex diseases such as cancer, diabetes, and autoimmune disorders. Biosimilars provide cost-effective alternatives to branded biologics while maintaining comparable safety, efficacy, and quality, making them attractive to healthcare providers and patients. The rising prevalence of chronic diseases and expanding patient populations are driving their adoption globally. Regulatory approvals and supportive frameworks in major markets are encouraging the development and commercialization of biosimilars. Continuous innovation in biologic development and manufacturing processes is enhancing the availability and diversity of biosimilar products.

Healthcare cost containment and the need for more sustainable medical treatments are further fueling the biosimilars market. Increased awareness among physicians and patients about biosimilar efficacy and safety is promoting their integration into treatment protocols. Patent expirations of several blockbuster biologics are creating significant opportunities for biosimilar manufacturers. Emerging markets with growing healthcare infrastructure are witnessing accelerated adoption due to affordability and accessibility advantages. With their ability to reduce treatment costs, expand patient access, and maintain therapeutic outcomes, biosimilars are poised to play a pivotal role in the global pharmaceutical landscape.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biosimilars-market?sp

Biosimilars Market: Major Players

Amgen Inc., Pfizer Inc., Sandoz Group AG, Teva Pharmaceuticals USA, Inc., Biogen, Biocon Biologics Inc., Boehringer Ingelheim International GmbH, Samsung Bioepis, Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG and among others.

Segment Covered in the Biosimilars Market:

➥ By Product Type: Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Insulin, Anti-coagulants, Erythropoietin, Granulocyte Colony Stimulating Factor, Follitropin, Interferons, Others

➥ By Application: Oncology, Chronic Diseases, Autoimmune Diseases, Infectious Diseases, Growth Hormone Deficiency, Hematology, Others

Research Process:

Both primary and secondary data sources have been used in the Biosimilars Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Biosimilars Market Research Industry:

➠ Who leads the Biosimilars industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Biosimilars market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Biosimilars market growth?
➠ What are the dominant sales and distribution strategies in the Biosimilars industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biosimilars-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.